User:Mr. Ibrahem/Bamlanivimab/etesevimab

Bamlanivimab/etesevimab is a combination of medications used to treat or prevent COVID-19. They are used in those who do not currently require hospitalization but are at high risk of getting worse. It is much less effective for the Omicron variant. It is given by injection into a vein.

Side effects may include pain at the site of injection and allergic reactions including anaphylaxis. While there is no evidence of safety in pregnancy, such use may still be recommended. It is a combination of bamlanivimab and etesevimab, two monoclonal antibodies that bind to different parts of the surface spike protein of SARS‑CoV‑2.

The combination has emergency use authorization in the United States. Request for approval has been withdrawn in Europe. As of January 2022 they continued to be distributed to part of the United States with low rates of resistance. The combination costs the United States government about 2,100 USD per dose as of 2021.